OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Apple Turns 50: From Garage Startup to AI Crossroads 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Company Announcement no. 26/2016
To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 20 December 2016
Veloxis Pharmaceuticals Announces Financial Calendar for 2017
Veloxis Pharmaceuticals A/S (OMX: VELO) today announced its financial calendar for 2017.
29 March, 2017: 2016 Annual Report.
7 April, 2017: 2017 Annual General Meeting.
16 May, 2017: Q1 Interim Report – for the period 1 January to 31 March, 2017.
16 August, 2017: Q2 Interim Report – for the period 1 January to 30 June, 2017.
14 November, 2017: Q3 Interim Report – for the period 1 January to 30 September, 2017.
For more information, please contact:
Craig Alexander Collard
President & CEO
Phone: +1 919 591 3065
Email: [email protected]
About Veloxis Pharmaceuticals
Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company committed to improving the lives of transplant patients. A Danish company, Veloxis Pharmaceuticals A/S operates in the U.S. through Veloxis Pharmaceuticals Inc., a wholly-owned subsidiary headquartered in Cary, North Carolina, USA and maintains a second corporate office in Edison, New Jersey, USA. Veloxis has successfully developed Envarsus XR (tacrolimus extended-release tablets) based upon the company's unique and patented delivery technology, MeltDose®, which is designed to enhance the absorption and bioavailability of select orally administered drugs. The company is focused on the direct commercialization of Envarsus XR in the US, expansion of partnerships for markets around the world, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.
For further information, please visit www.veloxis.com.
Attachments:http://www.globenewswire.com/NewsRoom/AttachmentNg/541b8815-bce1-4a91-828e-c684383bc1e6
